Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the drug RAD001 in combination with another chemotherapy
drug, Carboplatin, as well as radiation therapy in the treatment of esophageal cancer.
Because RAD001 has not been used in this combination before, it is not clear which dose will
be best when used in combination.
The standard of care for patients who have esophageal cancer that has not moved to other
areas of the body (non-metastatic) includes a combination of chemotherapy, radiation therapy
and possibly surgery. If the patient chooses to participate in this study, the patient will
receive chemotherapy and radiation therapy. The patient will possibly also have surgery to
have the cancer removed. This decision will be made by the treating physicians. All of the
chemotherapy the patient will receive on the study is considered standard chemotherapy for
esophagus cancer. The investigators do not know as of yet if the drug called RAD001 will help
improve the treatment for patients with this disease. RAD001 is a pill that has been used in
many other types of cancer and has been proven to be effective in other cancers such as
kidney cancer.